Fredric N Eshelman
CIK 1033409 · Executive Chairman · last filed 2022-10-26
Fredric N Eshelman is an Executive Chairman who has filed 114 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing shows the insider was granted $30.0M of ARAV on Oct 26, 2022. Across all open-market trades the lifetime net is +$26.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $121.5M across reported positions. 91 SEC filings were submitted jointly with PHARMACEUTICAL PRODUCT DEVELOPMENT INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PPDI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
929 NORTH FRONT STREET
WILMINGTON, NC 28401
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Aravive, Inc. (ARAV) Delisted | Executive Chairman | 25,517,889 | $0.04 | $1.02M | $0 | 3 | 2022-10-26 |
| HYPERION DEFI, INC. (EYEN) Delisted | Director | 20,236 | $15.82 | $320.1K | $3.35M | 5 | 2021-11-22 |
| LQDA | 10%+ Owner | 2,776,783 | $43.74 | $121.46M | -$16.43M | 7 | 2021-01-27 |
| G1 Therapeutics, Inc. (GTHX) Delisted | Director | 3,689,151 | $7.15 | $26.38M | $9.43M | 6 | 2020-06-12 |
| MEDICINES CO /DE (MDCO) Delisted | Executive Chairman | 2,076,686 | — | — | $36.41M | 8 | 2018-06-04 |
| Furiex Pharmaceuticals, Inc. (FURX) Delisted | Director | 2,715,188 | — | — | $35.19M | 28 | 2013-07-02 |
| PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted | Executive Chairman | 0 | — | — | -$41.16M | 50 | 2011-12-06 |
Recent Filings
114 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-10-26 | Aravive, Inc. (ARAV) Delisted | Grant (A) | +32,612,240 | $30.00M | EDGAR |
| 2022-09-26 | Aravive, Inc. (ARAV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-31 | Aravive, Inc. (ARAV) Delisted | Grant (A) | +1,720,432 | $4.00M | EDGAR |
| 2021-11-22 | HYPERION DEFI, INC. (EYEN) Delisted | Grant (A) | +6,963 | $0 | EDGAR |
| 2021-01-27 | LQDA | Sell (S) | −3,524,324 | -$11.01M | EDGAR |
| 2021-01-21 | LQDA | Sell (S) | −294,480 | -$873.6K | EDGAR |
| 2021-01-15 | LQDA | Sell (S) | −75,718 | -$228.7K | EDGAR |
| 2021-01-11 | LQDA | Sell (S) | −429,442 | -$1.33M | EDGAR |
| 2020-12-28 | LQDA | Sell (S) | −15,898 | -$49.9K | EDGAR |
| 2020-12-01 | LQDA | Sell (S) | −800 | -$2.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.